Research opportunity and event information may be provided on behalf of an external organization. Please refer to the contact information within each listing to identify the contact for questions or comments.
A new study for Ocrevus and Kesimpta users!
This research aims to understand changes in MS symptoms between doses for people with MS who are treated with ocrelizumab (Ocrevus) or ofatumumab (Kesimpta). We’re conducting this study with the pharmaceutical company Novartis and their consultant STATLOG Inc.
Participation involves completing a set of questionnaires at enrollment, and before and after your next two treatment doses. Participants will be compensated $50 for each set of questionnaires that is completed, up to $250 total.
You may be eligible for this study if you:
- live in the United States
- have been diagnosed with relapsing MS, secondary progressive MS, or clinically isolated syndrome (CIS)
- are currently being treated with either Kesimpta or Ocrevus
- Kesimpta users: treatment start was at least 6 months ago
- Ocrevus users: treatment start was at least 1 year ago, and most recent dose was at least 3 months ago
If you are interested in participating in this study, please email us at info@iconquerms.org and we will send you further information. If you don’t meet the eligibility criteria now but expect to do so in the future, please get in touch to let us know.
Discover 40+ strategies to turn the tide on your symptoms at the Multiple Sclerosis and Neuroimmune Summit!
ACP is proud to participate in the Multiple Sclerosis and Neuroimmune Summit 2.0, hosted by Dr. Terry Wahls. This conference aims to provide empowerment and support for everyone affected by this autoimmune disease. There will be an encore session the weekend of August 30th to September 1st. Register for free and be sure to check out our session on “The Importance Of Your Role In Research For MS Care”!
Don't Miss We Are ILL's Wellness Week(end) This Fall!
We Are ILL is hosting its fifth annual Wellness Week(end) from November 1-3 in Atlanta, GA. This one-of-a-kind gathering is specially designed for Black women living with MS and their spouses, partners, caregivers, friends, and family members. Join We Are ILL for a transformative weekend of empowerment and connection! To purchase tickets or learn more, visit wearewellnessweekend.com.
Trouble Sleeping?
The CALM study examines a behavioral intervention to treat insomnia in adults with multiple sclerosis. This study is conducted by researchers at the University of Kansas Medical Center; all study visits are conducted virtually.
Eligible individuals will be randomized to either one-on-one cognitive behavioral therapy for insomnia (CBT-I) or a sleep and lifestyle education program. Both programs involve meeting one-on-one with a trained interventionist 1x/week for 6 weeks via Zoom. Participants are asked to complete questionnaires at baseline, 6 weeks, and 6 months.
Participants will be compensated $50 for completing the baseline assessment, $50 for completing the 6-week assessment, and $100 for completing the 6-month assessment, receiving up to $200 total upon completion of the study.
You may be eligible for this study if you:
Are 18-65 years old
Have a diagnosis of relapsing-remitting or secondary progressive multiple sclerosis verified by your neurologist or physician
Are experiencing difficulty falling asleep, maintaining sleep, or waking up too early at least three nights per week for the past three months
Are able to meet virtually one time per week for six weeks and complete virtual assessments at baseline, 6 weeks, and 6 months
Other eligibility criteria to be assessed by phone call
If you are interested in participating in this study, please contact Eryen Nelson, study coordinator, via email at enelson5@kumc.edu or by phone at 913-945-7349.
If you have been diagnosed with Multiple Sclerosis, are 18 years old or older, and live in the United States, please consider participating in this research study that looks at the childhood experiences and well-being of people with MS.
Your participation would be greatly appreciated, and the results of this study can help us understand how early life experiences contribute to the well-being and mental health of people with MS. This may help mental health clinicians and physicians better meet the needs of people with MS. This survey will take approximately 40 minutes.
Participants who complete the survey will receive a $10 Amazon/Walmart/Target gift card!
You can access the survey here:
If you have any questions or concerns about this research study, please feel free to contact Caterina Obenauf, obenauf@tennessee.edu.
(This research study has been approved by the University of Tennessee, Knoxville Institutional Review Board. For more information about your rights as a participant, click here.)
Study participants recently spoke about their experiences taking part in the TEAAMS study on Brain Chat with the Nerdy Neurologist and RealTalk MS. Tune in and listen today!
A new topic for the Our Questions Have Power program!
When it comes to MS symptoms and how to manage them, what questions are most important to you? What symptom-related topics do you wish researchers were studying? Your questions are valuable and we invite you to share them through the Our Questions Have Power program on the iConquerMS website.
The Our Questions Have Power program was launched in March 2021 with an initial focus on COVID-19. Questions submitted by iConquerMS members have helped shape the COVER-MS vaccination study and are being shared with the research community to guide other efforts.
We’re now extending Our Questions Have Power to include a second topic: MS symptoms and their management and treatment. As before, you’re invited to share questions on this topic that you think should be studied and to vote on questions submitted by other iConquerMS members. We’ll share these questions with people affected by MS, researchers, healthcare professionals, advocates, and funders – and, together, we’ll work to launch research studies to answer those questions.
It’s easy to share your ideas and input in Our Questions Have Power!
